INmune Bio Inc. (INMB) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Inmune Bio Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.000 -- 00:00:00.400 Stand 00:00:00.220 -- 00:00:03.380 by, your program is about to begin. 00:00:06.580 -- 00:00:11.500 Greetings and welcome to the Immune Bio Second Quarter 2025 earnings call. 00:00:11.500 -- 00:00:14.420 At this time, all participants are in a listen-only mode. 00:00:14.420 -- 00:00:17.640 Later, you will have the opportunity to ask questions during the question and answer 00:00:17.640 -- 00:00:22.480 session. You may register to ask a question at any time by pressing star one on your 00:00:22.480 -- 00:00:27.160 touchtone phone. You may withdraw yourself in the queue by pressing star two. 00:00:27.160 -- 00:00:29.240 As a reminder, this conference is being recorded. 00:00:29.240 -- 00:00:33.580 A transcript will follow within 24 hours of this conference call. 00:00:33.580 -- 00:00:36.000 At this time, it is my pleasure to introduce Mr. 00:00:36.000 -- 00:00:39.260 Daniel Carlson, Head of Investor Relations at ImmuneBio. 00:00:39.260 -- 00:00:40.960 Daniel. 00:00:40.960 -- 00:00:43.900 Thank you, operator, and good afternoon, everyone. 00:00:43.900 -- 00:00:49.120 We thank you for joining us for the call for ImmuneBio's Second Quarter 2025 financial 00:00:49.120 -- 00:00:54.600 results. Presenting on today's call are David Moss, co-founder and CEO, 00:00:54.600 -- 00:00:57.760 Dr. CJ Barnum, Head of Neuroscience, and Dr. 00:00:57.760 -- 00:01:03.220 Mark Lodell, Chief Scientific Officer and co-founder of ImmuneBio. 00:01:03.220 -- 00:01:06.980 Before we begin, however, I remind everyone that except for statements of historical 00:01:06.980 -- 00:01:10.900 fact, the statements made by management in responses to questions on this conference 00:01:10.900 -- 00:01:15.360 call are forward-looking statements under the Safe Harbor Preserv...